Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07016633Phase 1Not Yet Recruiting

To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH

Role: lead

NCT04412616Phase 1Recruiting

ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

Role: lead

NCT06216041Phase 1Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects

Role: lead

NCT04126590Phase 1Unknown

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors

Role: lead

All 4 trials loaded